Skip to search formSkip to main contentSkip to account menu

HIV Protease Inhibitors [MoA]

Known as: HIV Protease Inhibitors, Human Immunodeficiency Virus Protease Inhibitors 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
The plasma concentrations of orally administered anti-human immunodeficiency virus protease inhibitors are significantly reduced… 
Highly Cited
2007
Highly Cited
2007
ABSTRACT Human immunodeficiency virus protease inhibitors (PIs) modestly affect the plasma pharmacokinetics of tenofovir (TFV… 
Highly Cited
2007
Highly Cited
2007
Although many of the clinically significant drug interactions of the anti-human immunodeficiency virus (HIV) protease inhibitors… 
Highly Cited
2006
Highly Cited
2006
ABSTRACT Parasite resistance to antimalarial drugs is a serious threat to human health, and novel agents that act on enzymes… 
Highly Cited
2004
Highly Cited
2004
Breast cancer resistance protein (BCRP) is a recently discovered ATP-binding cassette drug transporter. Hence, the full spectrum… 
Highly Cited
2003
Highly Cited
2002
Highly Cited
2002
ABSTRACT Intracellular accumulation of the protease inhibitors (PIs) saquinavir (SQV), ritonavir (RTV), and indinavir (IDV) was… 
Highly Cited
2001
Highly Cited
2001
Background—Human immunodeficiency virus protease inhibitors (HIV PIs) are associated with hyperlipidemia, hyperglycemia, and… 
Highly Cited
1999
Highly Cited
1999
Highly active antiretroviral therapy that includes human immunodeficiency virus (HIV) aspartyl protease inhibitors (PIs) causes a… 
Highly Cited
1998